Quick Answer
Yes. The EVO ICL (Implantable Collamer Lens) received FDA approval in March 2022. The approval was granted for adults aged 21 to 45 with myopia ranging from -3.00D to -20.00D, with or without astigmatism up to -4.00D. The approval was based on data from the CIRCA clinical trial, which followed 767 eyes over a minimum of 12 months and demonstrated high efficacy, safety, and patient satisfaction.
Detailed Explanation
FDA approval of a medical device is a rigorous process that requires manufacturers to demonstrate both safety and effectiveness through well-designed clinical studies. Understanding what EVO ICL’s approval means — and what it covers — helps patients evaluate the procedure with appropriate confidence.
The regulatory history:
The ICL (Implantable Collamer Lens) family has a longer FDA history than many patients realize. STAAR Surgical received FDA approval for the original Visian ICL in 2005. The EVO ICL is an evolved iteration of this platform, incorporating the KS-AquaPORT — a small central port in the lens that allows aqueous humor to flow freely through the anterior segment. This design change eliminated the need for a preparatory laser peripheral iridotomy that older ICL models required.
The EVO ICL’s additional approval was required because it represents a design modification that needed independent safety and efficacy evaluation.
The CIRCA clinical trial:
The FDA approval was based on the CIRCA (Clinical Investigation Report for the CARFlow ICL) study. Key data from this trial:
- 767 eyes from 396 patients enrolled
- 12-month primary efficacy endpoint, with continued follow-up
- 99.4% of eyes achieved uncorrected distance visual acuity (UDVA) of 20/40 or better
- 94.2% of eyes achieved 20/20 or better UDVA
- 98.1% of eyes achieved UDVA within one line of their best spectacle-corrected visual acuity (BSCVA) from before surgery
- Patient satisfaction rate: 99.4% reported being satisfied or very satisfied with their results
- Safety index: 1.01 (meaning the average eye could see slightly better without glasses after surgery than with glasses before surgery)
These outcomes represent exceptional performance on the FDA’s standard metrics for refractive surgery approval.
What the approval specifically covers:
The FDA approval is specific to:
- Patient age: 21 to 45 years
- Prescription range: -3.00D to -20.00D sphere, with cylinder (astigmatism) up to -4.00D
- Lens manufacturer: STAAR Surgical (the EVO ICL model specifically, not all ICL models)
- Procedure type: Elective phakic IOL implantation
Procedures performed outside these parameters are considered “off-label” use. Off-label use is legal and common in medicine, but it places additional responsibility on the surgeon to document clinical justification.
International approval context:
EVO ICL has been commercially available and CE-marked (approved) in Europe since 2011 — more than a decade before its FDA approval in the United States. It has been marketed in over 75 countries and has been implanted in over 1 million eyes globally. The extensive international clinical experience data was part of the evidence package submitted to the FDA and contributed to confidence in the technology’s safety profile.
For surgeons recognized for EVO ICL clinical excellence under the post-FDA approval standard, visit the EVO ICL Awards page.
What FDA approval means for patients:
FDA approval of a medical device means:
1. Manufacturing quality control: The manufacturer is subject to FDA inspection and quality standards. 2. Labeling requirements: The approved indications, contraindications, and instructions for use are clearly specified and must be followed. 3. Adverse event reporting: The manufacturer must track and report adverse events to the FDA. 4. Post-market surveillance: The FDA may require additional studies after approval to monitor long-term safety.
FDA approval does not mean the procedure is risk-free. All surgical procedures carry inherent risks. What approval establishes is that, in the studied patient population, the benefits of the procedure outweigh the risks when performed by trained surgeons on appropriately screened candidates.
The surgeon training component:
FDA approval of EVO ICL is tied to requirements for surgeon training and credentialing. STAAR Surgical administers a training program that surgeons must complete before they are authorized to implant the EVO ICL. This training covers preoperative sizing, implantation technique, and management of potential complications.
When evaluating a surgeon, confirming that they have completed STAAR Surgical’s EVO ICL training program and have performed a meaningful number of procedures is a relevant quality indicator.
Important Considerations
Some patients conflate FDA approval with absolute safety or superiority over all alternatives. FDA approval means the evidence base is sufficient to justify use in the approved population — it does not mean the procedure is right for every individual within that population.
It also means that procedures performed outside the approved parameters — such as using EVO ICL for patients younger than 21, older than 45, or with prescriptions outside the approved range — are not covered by the same evidence base and require more individualized clinical judgment.
Patients should also be aware that older ICL models (not EVO ICL) remain available at some practices. The EVO designation is important — the KS-AquaPORT design that eliminated the laser iridotomy step is specific to the EVO iteration, and older models without this feature carry a different risk profile.
What to Do Next
Confirm with any surgeon you consult that the lens they use is the EVO ICL model specifically — not an older STAAR Surgical ICL model or a non-STAAR alternative. Ask for the specific model name and STAAR Surgical’s catalog designation.
For a comprehensive overview of the procedure and what the approval-approved indications mean for your specific prescription, start with What Is EVO ICL Surgery?.
Related Questions
Does FDA approval mean insurance will cover it? No — FDA approval and insurance coverage are entirely separate determinations. See Does Insurance Cover EVO ICL? for why elective procedures remain excluded despite approval.
What are the risks the FDA evaluated? Read What Are the Risks of EVO ICL Surgery? for the complete safety profile as evaluated by clinical studies.
How do I find a surgeon certified to perform EVO ICL? See How Do I Find the Best EVO ICL Surgeon? for guidance on identifying and vetting qualified providers.